drugset / Trial / NCT01594216
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase II investigator-Initiated trial of the Investigational Drug, Ruxolitinib, in combination with Exemestane in patients with estrogen-receptor positive advanced breast cancer. The objective of this study is to determine the preliminary safety and efficacy of the combination of exemestane and Ruxolitinib (INCB018424).
Timeline
- Start
- 2012-04
- Primary completion
- 2016-04
- Completion
- 2016-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exemestane | Small molecule | 25 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 25 mg | Oral |